How are operators approaching thrombus-heavy PAD, ALI, and ISR? Miranda and Raja discuss the role of the Rotarex™ Catheter System, IVUS-guided decision-making, and practical strategies for managing complex peripheral disease.
https://t.co/M5QOEwCBNe
“Under-promised and over-delivered.” Christopher L. Brown, MD, shares his early experience with Shockwave C2 Aero, highlighting improved deliverability, rewrap, and multivessel flexibility in complex calcified PCI.
https://t.co/ougFto875J @ShockwaveIVL#cardiotwitter
New today in @CathLabDigest! Haris Usman, MD, MS, FACC, FSCAI, and Ramzan M. Zakir, MD, RPVI, FACC, FSCAI, discuss the utility of the #DETOURSystem in challenging anatomical case examples that traditionally limit the feasibility of conventional endovascular or open surgical revascularization.
Read now in Cath Lab Digest online: https://t.co/dumpPfFkEo
Learn about the DETOUR System here: https://t.co/ycFuGmcK9i
#healthcareinnovation #cardiotwitter #endovascularinnovation #medicalinnovation
Fresh perspectives on IVUS + NIRS in PCI, experience with Shockwave C2 Aero, Kirtane on the ALL-RISE trial, PTAB with the DETOUR System in complex fem-pop disease, Rotarex for thrombus burden in ALI, and the latest from Dr. Kern. https://t.co/BtbQt4GmFa
#cardiotwitter#cardiology
Usman and Zakir highlight how the DETOUR™ System from Endologix may expand revascularization options in complex femoropopliteal disease, including long lesions, prior stents, and heavily calcified anatomy.
https://t.co/UmYnDglvuD
New MAUDE Analysis Highlights Real-World Mechanical Thrombectomy Complications
At SIR 2026, Chloe Issa, MD, and Sarah Montaquila, DO, revealed a key gap between complication frequency and severity in venous and pulmonary thrombectomy systems.
https://t.co/Ft4gS3S28N
New Insights on Thrombectomy in Atrial Fibrillation-Related Stroke
At SIR 2026, Dr Wahood discussed how earlier detection, shifting practice patterns, and narrowing disparities are reshaping mechanical thrombectomy outcomes in stroke patients with AF.
https://t.co/ERurr6Swr9
What can firsthand experience reveal about the new Shockwave C2 Aero? CLD's Partner Spotlight features practical insights into how #ShockwaveC2Aero is being used to approach coronary calcium modification in real-world cases. Find more:
https://t.co/9jR3StUktQ @ShockwaveIVL
As cardiovascular procedures continue shifting to the ASC, Marc Toth highlights 4 key considerations for a successful outmigration strategy, including design, digital monitoring, virtual rehab, and long-term scalability.
https://t.co/BEbOlg7bSY #cardiotwitter#ASC#cardiology
IVL keeps advancing, with new patent activity, FIH platform use, pivotal coronary trial progress, and real-world data supporting an IVL-first strategy in complex calcified disease. Latest: https://t.co/VvtlmpeAXs
@ShockwaveIVL@BostonSci@fastwavemedical@CagentVascular
What can firsthand experience reveal about the new Shockwave C2 Aero? CLD's Partner Spotlight features practical insights into how #ShockwaveC2Aero is being used to approach coronary calcium modification in real-world cases. Find more:
https://t.co/j9Ou7aBBWV @ShockwaveIVL
What does a high-functioning hybrid OBL/ASC look like in practice? Timothy Dao, MD, and Rikesh Patel, MD, share how HeartPlace is using careful case selection, efficiency, and safety to expand outpatient cardiovascular care in Texas. https://t.co/VsdtQztyK9 #cardiotwitter#ASC
Microplastics as Triggers of Immunothrombosis: Linking Environmental Exposure to Cardiovascular Events
Small particles, serious consequences. Emerging research links everyday exposure to immune-driven clotting and cardiovascular risk.
Learn more: https://t.co/6Svg8w7L5L @hmpVDM
Advanced heart failure specialist Matthew Gonzalez, MD, shares practical insights for using the CardioMEMS™ HF System, made by Abbott, in real-world practice.
Read more: https://t.co/nm7mPGZSKp
#CardioMEMS#cardiotwitter@AbbottCardio#HeartFailure
What happens when insurance decisions stand in the way of timely care for chronic limb-threatening ischemia? Lata et al share a case; commentary by Nanjundappa et al.
Read more: https://t.co/ZaOYGoJQyu
#medtwitter@InvasiveCardiol@hmpVDM
Coronary interventions are moving into ASCs. What’s your system’s plan? Marc Toth and Derek Mitzel outline why an ambulatory strategy now needs clear case selection, escalation pathways, staffing, and a system-wide access + growth playbook.
https://t.co/hYnPthBqSC #cardiotwitter
RCT data are coming for pelvic vein embolization. Co-PI @RonaldWinokurMD on the EMBOLIZE trial: venography vs venography + ovarian/pelvic vein embolization for pelvic venous disease pelvic pain (pain + QoL).
https://t.co/tK1e87fCYj @PenVascular
Ultra-high-pressure balloon strategy in complex PCI: @KAlaswadMD shares how the OPN NC (35 atm) can tackle resistant calcium/underexpanded stents, with trial data (eg, VICTORY) supporting stent expansion comparable to IVL in selected cases.
https://t.co/oncEivik9L
Leapfrog is expanding ASC public reporting: nearly 4,000 centers will be rated starting late July 2026, using CMS measures, accreditation-verified standards, and a redesigned ASC Survey 2.0.
https://t.co/rIsSaxPPcV #cardiotwitter#cardiology#medtwitter
Daniel Aboyeji, RN, BSc, asks: During arrest from abrupt unprotected left main occlusion, is a brief “controlled pause” in CPR (<1-2 min) ever justified to regain guide/wire position and restore flow? @MortonKern + colleagues weigh in https://t.co/8Vm1LKUYGZ #cardiotwitter